相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Immunology
Yaki Saciuk et al.
Summary: A retrospective cohort study in Israel showed that a third dose of the BNT162b2 vaccine provides added protection against SARS-CoV-2 infection, especially for those vaccinated six months ago. The vaccine's effectiveness was found to be 92.9% in terms of prevention of infection, highlighting the importance of booster doses in maintaining immunity.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Virology
Derya Caglayan et al.
Summary: This study evaluated the antibody levels after CoronaVac vaccination and heterologous/homologous booster administration among healthcare workers in Turkey. The results showed a decline in antibody levels over time, with a reduction of 61.4% or more in some participants. Chronic disease and the age group of 36-50 were identified as predictors for low antibody response. Participants who received the BNT162b2 vaccine showed a 104.8-fold increase in antibody levels.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Article
Medicine, General & Internal
Sue Ann Costa Clemens et al.
Summary: A study was conducted to evaluate the safety and immunogenicity of a third dose of heterologous or homologous vaccines in Brazilian adults who had previously received two doses of CoronaVac. The results showed that a third dose of heterologous vaccines (recombinant adenoviral vectored vaccine or mRNA vaccine) significantly increased immune responses and could improve protection against infection.
Article
Immunology
Ritthideach Yorsaeng et al.
Summary: The immune response after the AZD1222 booster in individuals who received the two-dose CoronaVac vaccine was found to be limited, with lower neutralizing activity against the wild type and variants. However, the AZD1222 booster significantly enhanced the immune response, resulting in higher antibody levels and neutralizing activity.
Article
Cell Biology
Yihao Liu et al.
Summary: SARS-CoV-2 inactivated vaccines have demonstrated significant efficacy in reducing severe illness and death. Despite a decline in humoral immunity over time, memory B and T cells remain detectable and can provide a quick recall response. A third booster dose enhances the immune response and improves the durability of protective immunity. Additionally, healthcare workers with low serological response to two doses still possess immune memory that can be quickly recalled by a third dose.
Letter
Virology
Ali Umit Keskin et al.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Article
Health Care Sciences & Services
Monica M. Robles-Fontan et al.
Summary: After implementing strict vaccine mandates, Puerto Rico saw a substantial decrease in laboratory-confirmed SARS-CoV-2 cases, with over 70% of the population vaccinated. The mRNA-1273 and BNT162b2 vaccines were highly effective across all age groups, while the Ad26.COV2.S vaccine had lower effectiveness. Vaccination provided additional protection against COVID-19 hospitalizations and deaths, which did not wane over time for those who were infected.
LANCET REGIONAL HEALTH-AMERICAS
(2022)
Article
Biochemical Research Methods
Elena Riester et al.
Summary: The Elecsys Anti-SARS-CoV-2 S immunoassay demonstrated reliable performance with high specificity and sensitivity for detecting anti-SARS-CoV-2 antibodies, outperforming other commonly used similar assays.
JOURNAL OF VIROLOGICAL METHODS
(2021)
Article
Medicine, General & Internal
Alasdair P S Munro et al.
Article
Medicine, General & Internal
Ronen Arbel et al.
Summary: Among 843,208 participants in Israel aged 50 years or older who had received two doses of the BNT162b2 vaccine at least 5 months earlier, those who received a booster had 90% lower mortality due to Covid-19 than those who did not receive a booster during the 54-day study period.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Einav G. Levin et al.
Summary: A study in Israel revealed that waning immunity after receiving two doses of the BNT162b2 vaccine led to an increase in the incidence of SARS-CoV-2 infection. Levels of spike-binding IgG and neutralizing antibodies decreased more significantly in men, individuals aged 65 or older, and immunosuppressed individuals in a longitudinal study involving nearly 4000 healthcare workers.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Stephane Marot et al.
Summary: This study found that SARS-CoV-2 infection can induce neutralizing antibody response correlated with antibody levels, but this neutralizing activity declines after two months post-disease onset, suggesting the need for maintaining infection prevention measures and considering periodic vaccination boosts.
NATURE COMMUNICATIONS
(2021)
Article
Immunology
Rima Moghnieh et al.
Summary: A study conducted in Lebanon found that administering a BNT162b2 booster dose to COVID-19-naive individuals who had received two doses of the BBIBP-CorV vaccine was safe and resulted in significantly higher anti-spike IgG levels compared to homologous BNT162b2 immunization.
Article
Geriatrics & Gerontology
Istvan Valyi-Nagy et al.
Summary: This study compared the humoral and T cell-mediated immune responses elicited by BBIBP-CorV and BNT162b2 vaccines against the SARS-CoV-2 virus, revealing significant quantitative and qualitative differences between the two. BBIBP-CorV vaccine induced high levels of antibody responses in healthy individuals, while BNT162b2 showed slightly higher T cell responses.
Article
Biochemistry & Molecular Biology
David S. Khoury et al.
Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.
Article
Medicine, General & Internal
Nawal Al Kaabi et al.
Summary: This interim analysis of an ongoing randomized trial in the UAE and Bahrain evaluated the efficacy of two inactivated COVID-19 vaccines in preventing symptomatic cases and adverse events in healthy adults. The study found that both vaccines significantly reduced the risk of symptomatic COVID-19 compared to the control group, with efficacy rates of 72.8% and 78.1%. Serious adverse events were rare across all groups.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Letter
Medicine, General & Internal
Madhumita Shrotri et al.
Letter
Medicine, General & Internal
Aziz Sheikh et al.
Article
Biochemistry & Molecular Biology
Joana Barros-Martins et al.
Summary: A study found that booster vaccination with BNT162b2 in healthcare professionals previously vaccinated with ChAdOx-1 nCoV-19 elicited more neutralizing antibodies and higher frequencies of virus-specific T cells. Additionally, BNT162b2 induced high titers of neutralizing antibodies against variants of concern, such as B.1.1.7, B.1.351, and P.1.
Article
Medicine, General & Internal
Moriah Bergwerk et al.
Summary: Among fully vaccinated health care workers, breakthrough infections with SARS-CoV-2 were correlated with neutralizing antibody titers during the peri-infection period. Most breakthrough infections were mild or asymptomatic, although persistent symptoms did occur.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
S. J. Thomas et al.
Summary: BNT162b2 vaccine remains highly effective and safe over the course of 6 months post-vaccination, with efficacy rates ranging from 86% to 100% across different demographics and risk factors for Covid-19. The vaccine also shows a high efficacy against severe disease, with particularly promising results observed in South Africa against the B.1.351 variant.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
